- Home
- PTY vs GPCR Comparison
PTY vs GPCR Comparison
Compare PTY & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- GPCR
- Stock Information
- Founded
- PTY 2002
- GPCR 2016
- Country
- PTY United States
- GPCR United States
- Employees
- PTY N/A
- GPCR N/A
- Industry
- PTY Investment Managers
- GPCR
- Sector
- PTY Finance
- GPCR
- Exchange
- PTY Nasdaq
- GPCR Nasdaq
- Market Cap
- PTY 2.2B
- GPCR 1.8B
- IPO Year
- PTY N/A
- GPCR 2023
- Fundamental
- Price
- PTY $14.65
- GPCR $33.41
- Analyst Decision
- PTY
- GPCR Buy
- Analyst Count
- PTY 0
- GPCR 5
- Target Price
- PTY N/A
- GPCR $86.80
- AVG Volume (30 Days)
- PTY 550.4K
- GPCR 836.2K
- Earning Date
- PTY 01-01-0001
- GPCR 11-13-2024
- Dividend Yield
- PTY 9.65%
- GPCR N/A
- EPS Growth
- PTY N/A
- GPCR N/A
- EPS
- PTY N/A
- GPCR N/A
- Revenue
- PTY N/A
- GPCR N/A
- Revenue This Year
- PTY N/A
- GPCR N/A
- Revenue Next Year
- PTY N/A
- GPCR N/A
- P/E Ratio
- PTY N/A
- GPCR N/A
- Revenue Growth
- PTY N/A
- GPCR N/A
- 52 Week Low
- PTY $11.92
- GPCR $26.61
- 52 Week High
- PTY $14.88
- GPCR $66.38
- Technical
- Relative Strength Index (RSI)
- PTY 61.38
- GPCR 41.58
- Support Level
- PTY $14.35
- GPCR $29.48
- Resistance Level
- PTY $14.59
- GPCR $38.48
- Average True Range (ATR)
- PTY 0.09
- GPCR 2.86
- MACD
- PTY -0.00
- GPCR -0.59
- Stochastic Oscillator
- PTY 73.17
- GPCR 30.90
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.